AG
ONC

Aperio Group’s BeOne Medicines Ltd ONC Stock Holding History

Aperio Group’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$6.58M Buy
25,462
+798
+3% +$220K 0.02% 715
2020
Q3 		$7.07M Buy
24,664
+7,999
+48% +$1.88M 0.02% 609
2020
Q2 		$3.14M Buy
16,665
+1,361
+9% +$222K 0.01% 912
2020
Q1 		$1.88M Buy
15,304
+5,401
+55% +$845K 0.01% 1036
2019
Q4 		$1.64M Sell
9,903
-568
-5% -$94.4K 0.01% 1181
2019
Q3 		$1.28M Buy
10,471
+1,260
+14% +$167K 0.01% 1269
2019
Q2 		$1.14M Buy
9,211
+2,838
+45% +$360K ﹤0.01% 1344
2019
Q1 		$841K Buy
6,373
+3,511
+123% +$474K ﹤0.01% 1445
2018
Q4 		$401K Buy
+2,862
New +$380K ﹤0.01% 1812
2018
Q3 		– Sell
-1,355
Closed -$209K – 2302
2018
Q2 		$209K Buy
1,355
+136
+11% +$24.3K ﹤0.01% 2150
2018
Q1 		$205K Sell
1,219
-1,692
-58% -$229K ﹤0.01% 2131
2017
Q4 		$284K Hold
2,911
– – ﹤0.01% 1971
2017
Q3 		$301K Buy
+2,911
New +$217K ﹤0.01% 1918

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Aperio Group's ONC Position: Q4 2020 in Review

Aperio Group increased its BeOne Medicines Ltd (ONC) stake by 3.2% in Q4 2020, buying an estimated $220K and bringing the position to 25,462 shares worth $6.58M. The position accounts for 0.02% of the portfolio, ranked #715.

Aperio Group first reported a position in ONC in Q3 2017 and has held it in 13 quarters since. The position peaked at $7.07M in Q3 2020. 248 funds tracked by Wall St. Rank hold ONC as of Q4 2020.

  • Aperio Group held 25,462 shares of BeOne Medicines Ltd worth $6.58M as of Q4 2020.
  • Aperio Group bought 798 BeOne Medicines Ltd shares in Q4 2020, an estimated $220K.
  • BeOne Medicines Ltd made up 0.02% of Aperio Group's portfolio in Q4 2020, its #715 holding.
  • Aperio Group first reported a position in BeOne Medicines Ltd in Q3 2017 and has held it in 13 quarters since.
  • Aperio Group's BeOne Medicines Ltd position peaked at $7.07M in Q3 2020.
  • 248 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.